-
The JPM Healthcare Conference is the industry’s largest and most informative healthcare investing symposium. It connects global industry leaders, fast-growing emerging companies, innovative technology creators and members of the investment community.
-
Pioneer of health economics examine the interdependencies of the health ecosystem that are often overlooked when considering only one silo.
-
AI in biopharmaceuticals to highlight how AI-powered technologies can revolutionize drug discovery, accelerate development timelines, improve patient accessibility, drive faster innovation, and significantly reduce operating costs.
-
Panelists will include David Rhew (Global Chief Medical Officer and Vice President of Health, Microsoft), Sean Tunis (Director, Rubix Health), Peter Ehrhardt (Senior Associate, Simon-Kucher) and Poonam Alaigh (former Acting Under Secretary to health, United States). Department of Veterans Affairs).
WARREN, NJ, December 26, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual JP Morgan Healthcare Conference in San Francisco, California.
Event Details
Date:
Monday January 13, 2025
Location:
Marines’ Memorial Club & Hotel, 609 Sutter St., San Francisco, CA 94102
Time (PST):
2:00 p.m. – 2:30 p.m. – AI in biopharmaceuticals: the next frontier of medical innovation
Panelists:
Dr. David Rhew – Global Chief Medical Officer and Vice President of Healthcare, Microsoft (Nasdaq: MSFT)
Dr. Sean Tunis – Director, Rubix Health
Mittul Mehta – Chief Information Officer and Head of Tevogen.AI, Tevogen Bio
2:30 p.m. – 3:15 p.m. – Afternoon coffee break
3:15 p.m. – 4:00 p.m. – Pioneering health economics: balancing access and outcomes
Victor Sordillo – MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio
Peter Ehrhardt – Senior Partner at Simon-Kucher & Partners
Dr. Poonam Alaigh – former Acting Undersecretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health
Dr. Sean Tunis – Director, Rubix Health; principal investigator, Tufts Center for Health Value and Risk Assessment; Business Mentor, Johns Hopkins Tech Ventures
Dr. Ryan Saadi – Founder and CEO, Tevogen Bio
4:00 p.m. – 6:00 p.m. – Reception and cocktails
For inquiries regarding additional event details, please contact [email protected].
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T cells, to develop off-the-shelf, genetically unmodified precision T cell therapies for treatment of infectious diseases, cancers and neurological disorders. aimed at addressing the unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in today’s healthcare era relies on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its core intellectual property assets are fully owned by the company and are not subject to any third-party licensing agreements. These assets include three issued, nine pending U.S. patents and twelve pending non-U.S. patents, two of which relate to artificial intelligence.
